PFS Partners’s Trevi Therapeutics TRVI Stock Holding History

PFS Partners’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Hold	0	–	-$42.1K	–	573
2025 Q2	–	Hold	0	–	–	–	174

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

PFS Partners's TRVI Position: Q2 2026 in Review

PFS Partners held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 79,000 shares worth $1.47M. The position accounts for 0.6% of the portfolio, ranked #24.

PFS Partners first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

PFS Partners held 79,000 shares of Trevi Therapeutics worth $1.47M as of Q2 2026.
PFS Partners left its Trevi Therapeutics share count unchanged in Q2 2026.
Trevi Therapeutics made up 0.6% of PFS Partners's portfolio in Q2 2026, its #24 holding.
PFS Partners first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.